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Abstract
Background In recent years repeat sentinel node (SN) biopsy
has been proven to be feasible in local breast cancer recur-
rence (LBCR). However, in these patients SNs outside the
ipsilateral axilla are frequently observed. This study evaluates
the contribution of SPECT/CT for SN localization and surgi-
cal adjustment in LBCR patients.
Methods SN biopsy was performed in 122 LBCR patients
(median age 60.5 years, range 24–87), enrolled from August
2006 to July 2015. Median disease-free time lapse was
109.5 months (range 9–365). Axillary lymph node dissection
(ALND) had previously been performed in 55 patients, SN
biopsy in 44, both techniques in 13 and fine-needle aspiration
in 10. Primary breast cancer treatment included radiotherapy
in 104 patients (85.3 %) and chemotherapy in 40 (32.8 %).
Preoperative lymphatic mapping, using planar scintigraphy
(PS) and SPECT/CT included report of SN location according
to lymph node territory. In case of a territorial PS-SPECT/CT
mismatch, surgery was adjusted according to SPECT/CT
findings.
Results SPECT/CT SN visualization rate was higher than PS
(53.3% vs. 43.4%, p n.s.) with, in total, 19 additional SN (118
vs. 99, p n.s.). PS-SPECT/CT territory mismatch, found in
60 % (39/65) of patients with SN visualization, led to surgical
adjustment in 21.3 % (26/122) of patients. The SN procedure
was finally performed in 104 patients resulting in a 65.7 %
surgical retrieval rate with a total of 132 removed SNs (1.86/
patient). SNmetastases were found in 17/71 patients (23.9 %),
in 16 of them (94 %) in ipsilateral basins outside the axilla or
in the contralateral axilla.
Conclusion Using SPECT/CT there is a trend to visualize more
SNs in LBCR, providing at the same time important anatomical
information to adjust intraoperative SN procedures. The addition
of SPECT/CT to the standard imaging protocol may lead to
better staging mainly in patients presenting drainage outside the
ipsilateral axilla.
Keywords SPECT/CT . Sentinel node .
Lymphoscintigraphy . Recurrent breast cancer . Radioguided
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Background
Breast cancer is the most frequent cancer in women with 1.67
million new cases in 2012, ranking second in frequency
worldwide [1]. The highest incidence is in Western Europe,
reaching over 96 new cases per 100,000. Breast cancer mor-
tality dropped over the last few decades due to earlier diagno-
ses by screening, increasing patients awareness and improved
comprehensive care [2]. To achieve individualized patient
treatment one should take into account staging, biological
cancer information, personal preferences (patient and treating
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physician) among other variables. Nowadays, a broad thera-
peutic arsenal is at our disposal: different forms of surgery,
radio- and chemotherapy, endocrine therapy, and more specif-
ic targeted therapy [3].
Lymph node status is the most important prognostic factor
in primary breast cancer [4]. This is acknowledged in many
guidelines, as in the most recent ESMOguidelines in 2015 [5].
It is likely that nodal status is also prognostic in locally recur-
rent breast cancer. Therefore, knowledge of nodal status influ-
ences regional treatment strategies, particularly radiotherapy,
and may also enforce the indication for adjuvant systemic
(re-)treatments with curative intention [6]. Since the introduc-
tion of the SN procedure in breast cancer planar scintigraphy
(PS) has been the basis for lymphatic mapping and has proven
to be an accurate tool for SN localization in primary cancer,
leading to detection rates of over 97 % and 98 % in series of
4800 [7] and 3681 patients [8], respectively.
Although relevant medical progress was reached in diag-
nosing and treating breast cancer in the last decade,
locoregional recurrence is still an issue after a full set of treat-
ment, ranging from approximately 3 % to near 30 % when
associated with distant metastasis [9, 10]. Contrary to high 5-
year survival rates known for primary breast cancer, relapse
breast cancer has a high mortality rate. Nonetheless, life ex-
pectancy is improving due to follow-up care after treatment,
and relapses are usually detected in asymptomatic stages [11].
Ten-year survival of breast cancer patients after local recur-
rence was around 20 % in the 1980s and 1990s [12] and
increased to approximately 35-45 % in more recent years
[13]. The last Dutch revision in 2015 on survival rates after
locoregional relapse showed a promising 49 % survival rate at
10 years [11].^
Against this background, the sentinel node (SN) procedure
has been introduced in breast cancer patients experiencing a
local relapse. This appears to be technically feasible, although
detection rates vary significantly from 62.1 % to 80.4 % [4–6,
14, 15] among several studies. Although several factors such
as tumour size and patient age have been described to alter
lymphatic drainage in patients at primary breast cancer pre-
sentation [16] in LCBR patients, previous treatment of the
primary cancer has incorporated additional variables that are
even more anatomically and physiologically destructive, in-
cluding surgery of both the axillary region and primary tu-
mour, systemic treatments and radiation therapy. This previ-
ous treatment frequently leads to a more complex and multi-
directional lymphatic drainage with a high incidence of SNs
outside the axilla suggesting the need for accurate localization
imaging modalities like single photon emission computed to-
mography in conjunction with computed tomography
(SPECT/CT) [17].
Early in 2015 the results from a multicentre prospective
study on the additional value of SPECT/CTover PS in various
malignancies, including primary breast cancer, coordinated by
the International Atomic Energy Agency (IAEA) were pub-
lished. On the basis of 1.182 enrolled breast cancer patients,
SN visualization increased from 87.6 % for PS to 91.3 %
when SPECT/CT was used additionally, and in 44 patients
only visualization on SPECT/CT enabled the SN procedure
[18]. SPECT/CT led to adjustments in anatomical SN locali-
zation and surgical management in 17% of the patients. So far
no studies have addressed the SPECT/CT impact in a similar
manner for breast cancer relapses.
The aim of this study was to evaluate whether the use of
SPECT/CT improved both visualization, and anatomical lo-
calization of the SN, and whether this additional information
may have had impact on the surgical approach and consequent
retrieval of SN in patients with local breast cancer relapse
(LBCR) scheduled for SN biopsy.
Material and methods
At the Netherlands Cancer Institute – Antoni van
Leeuwenhoek Hospital LBCR patients were incorporated to
the SN procedure from 2006 onward using both PS and
SPECT/CT, together with the introduction of SPECT/CT in
the protocol for lymphatic mapping in untreated breast cancer
patients [19]. All patients were restaged to exclude metastases
at distance following the Dutch breast cancer guidelines,
which include total body scanning with 18F-FDG PET/CT.
After giving informed consent from August 2006 to October
2015, 122 consecutive patients with repeat SNB for local
breast cancer relapse were studied following the protocol in-
cluding SPECT/CT. Their data were analysed retrospectively.
All patients were female with a median age of 60.5 years
(range 24 – 87) at time of LCBR and a median disease-free
time interval of 109.5 months (range 9 – 365). Primary tumour
surgery at initial presentation was breast sparing in 117 pa-
tients (96 %) and mastectomy in 5 (4 %). Lymphatic status at
first surgery was assessed with SNB procedure in 44 patients.
ALND alone was performed in 55 patients, 13 patients had
ALND after a positive SN. In 10 patients the N-stage was
assessed using clinical examination and ultrasound guided
fine needle aspiration. Metastases were found in 32 out of
112 patients who had undergone lymphatic surgery.
Systemic treatment was applied in 40 (32.8 %) patients and
radiotherapy either to the breast, axilla or both regions in 104
(85.3 %). Hormonal treatment information was not available
for all patients and could therefore not be included in this
evaluation. Patient characteristics are shown in Table 1.
Histological evaluation of the LBCR revealed ductal carci-
noma in 99 patients (81.2 %) and lobular in 18 (14.8 %). In
another five cases (4 %) the tumour type was adenocarcinoma
(not further specified), intracystic carcinoma, mucinous, meta-
plastic and papillary. In 59 patients tumours were located in
the left breast and in 63 in the right. The locations of the
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recurrences are shown in Fig. 1. Tumour sizes ranged from 3
to 70 mm with a median size of 15 mm. Hormone positive
receptors were present in 80 tumours, while 22 were triple
negative. Her-2 was positive in 12 patients.
Sentinel node procedure
In 113 patients (92.6 %) 99mTc-Nanocolloid (Nanocoll©; GE
Healthcare, Eindhoven, Netherlands) was administered by
intratumoural injection, the standard procedure in our hospi-
tal; either palpation-based or image-guided (ultrasound, ste-
reotactic, or using 125I-seed guided freehand-SPECT tumour
localization). Image-guided intratumoural injection was per-
formed in 43 patients (35 %). In nine patients (7 %) the injec-
tion was made either subcutaneously (n = 4), periareolar
(n = 3), or peritumourally (n = 2). Median injection activity
was 126.1 mBq (range 63.9-250.6). This dose matches the
recommendation for a 2-day SN procedure using intratumoral
tracer administration as validated in our institution [20].
Early planar scintigraphy was made at an average of 23 mi-
nutes after injection, and a late planar scintigraphy (PS) at an
average of 4 h. This is in agreement with the published EANM
guidelines for SN procedures in breast cancer [21]. PS
comprised 5-min static images in anterior and lateral/oblique
projections, 256 × 256 matrix, and zoom factor 1.0. A
57Cobalt flood source was used to delineate the body contour.
SPECT/CT was made at an average of 4.42 h after injection
using a dual-head SPECT/CT gamma camera (Symbia T®,
Siemens, Erlangen, Germany). SPECT parameters were:
128 × 128 matrix, zoom factor 1.0, and 180 degrees rotation
with 20 views per head (30 s per view). CT (130 Kv, 40 mAs,
B30s kernel, 2 mm axial reconstruction) was used for attenu-
ation correction and anatomical localization. For image read-
ing SPECT, CT, and fused SPECT/CT were displayed using
orthogonal multiplanar reconstruction, maximum intensity
projection and volume rendering.
As SNs were considered all lymph nodes with afferent
lymphatic vessel draining directly the injection site, or, in
cases of multiple nodes appearing with no afferent lymphatic
vessels on the lymphoscintigram, the first node appearing in
each basin [22]. The number of SNs and their draining basin
localization were evaluated separately on PS and SPECT/CT
images to establish the incremental value of SPECT/CT over
PS with respect to additional SNs or territorial mismatch fol-
lowing the criteria applied in a multicenter International
Atomic Energy Agency trial [18]. The anatomical territories
considered for the evaluation were the following: axillar level
I, II, and III, intramammary, interpectoral, clavicular, internal
mammary, all of them either ipsilateral or contralateral. Partial
mismatch was considered when a patient showed a sentinel
node that was correctly depicted and found, but also had one
or more sentinel nodes that were mismatches. Complete mis-
match between PS and SPECT/CT was considered whenever
sentinel nodes and/or anatomical location in a patient were
totally discordant with each other.
Surgery was performed either the same day or the day
following the radiotracer injection. Intra-operative SN
Fig. 1 Distribution of tumour relapse according to imaging technics and
surgical findings. Four quadrants were considered and the figures
depicted in the center of each breast stand for retroareolar tumours
Table 1 Description of patient characteristics, primary tumor
treatment, characteristics of relapse tumour, and activity and location of
radiotracer injection
Characteristic Median Range




Age at relapse (years) 60.5 24 - 87
Months to relapse 109.5 9 - 365






Relapse tumor size 15 mm 3 - 70 mm
Primary treatment
• Surgery
Breast conserving surgery 117 95.9 %
Mastectomy 5 4.1 %
ALND 68 55.7 %
SNB 57 46.7 %
ALND+ SNB 32 26.2 %
• Radiotherapy 104 85.2 %
• Chemotherapy 40 32.8 %
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detection was performed with a conventional gamma probe
(Neoprobe®, Neoprobe Corporation, Dublin, OH, USA). In
addition, patent blue dye was injected after anaesthesia induc-
tion in 76 (62.3 %) patients depending on the leading surgeon
preoperative decision. In principal, all SNs visualized on PS
and SPEC/CTwere to be removed. Adaptation of the surgical
procedure for SN biopsy was made in all cases with territorial
mismatch unless this concerned only a difference in axillary
levels (levels 1 to level 2, for example).
Factors associated with the SN detection were analysed
using logistic regression and statistical significance was
established at p < 0.05. The following variables related to
prior primary tumour were included in the analysis: age,
previous ALND or SNB, radiotherapy, chemotherapy, and
relapse variables as time to relapse, tumour size, total activity
administered, image guided injection or not. All of these
variables were added in order to identify possible causes and
confusion factors of altered sentinel node detection rates.
Continuous variables were checked for linearity and
categorized if shown to be non-linear. The analysis was
performed using R version 3.2.3 (2015-12-10).
Results
SPECT/CT visualized SNs in 65 patients (53.3 %) and PS
in 53 patients (43.4 %). This resulted in a 9.8 % visuali-
zation rate improvement (p n.s.). In the present study ear-
ly planar imaging visualized SNs in 22 patients (18 %),
whereas on delayed PS SNs were visible in 53 patients
(43.4 %), an increment of 25.4 %. A total of 118 SNs
were visualized on SPECT/CT and 99 on PS. Overall,
SN visualization rate was 63.2 % (43/68) for patients with
previous ALND with or without SN biopsy, and 38.6 %
(17/44) for patients with previous SN biopsy alone.
Results from a univariable (crude OR) and multivariable
(adjusted OR) logistic regression model are described in
Table 2. Older age showed to be the most important factor
in the multivariable model and was linearly associated
with a decreased detection rate (OR 0.95, 95%CI: 0.90-
0.99, unit is years). Alternative lymphatic drainage (SN
visualized outside the ipsilateral axilla) was found in 43 %
(28/65) of the patients and contralateral SN visualization
was present in 26 % (17/65) of the cases. Early PS visu-
alized 34 SNs in 22 patients (18 %).
SN distribution based on imaging is summarized in Fig. 2.
Territorial mismatches between PS and SPECT/CT
were observed in 39 out of the total of 65 patients
(60 %) with SN visualization. The most common iden-
tified territorial mismatches were: 1) no visualization on
PS accompanied by SPECT/CT visualization in the ip-
silateral axilla; this was found in seven cases (17.9 %).
2) Drainage to contralateral axilla not visualized on PS, but well
visualized on SPECT/CT in five patients (12.8 %) (Fig. 3).
3) Drainage to ipsilateral intramammary chain in five patients
(12.8 %) not visualized on PS and well visualized on SPECT/
CT (Fig. 4). 4) In three patients (7.7 %) putative SN visualization
on PS appeared to be due to tracer contaminations as shown on
SPECT/CT (Fig. 5)




OR p global p Nonlinear
Time to relapse 110 (62;228) 0.032 yes
Age 60 (51;67) 0.950 0.004 no
Tumor Size 15 (11;20) 1.000 0.881 no
ALND 0.013
No 54 1.000
Yes 68 2.502 0.014
SNB 0.112
No 65 1.000
Yes 57 0.559 0.113
Radiotherapy 0.020
No 18 1.000
Yes 104 0.275 0.031
Chemotherapy 0.513
No 82 1.000
Yes 40 1.289 0.514
Total activity 126 (116:135) 0.980 0.106 no
Image guided 0.427
No 79 1.000
Yes 43 1.354 0.428
Fig. 2 SN localization distribution using SPECT/CT imaging. Areas
depicted in clear grey are: axillar, clavicular, internal mammary chain,
and intramammary; bilateral areas with discontinued lines are depicting
intrapectoral nodes
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Surgical SN approach was adjusted using final SPECT/CT
information in 26 out of 122 patients (21.3 %). The SN
procedure was not performed in 18 patients with previous
ALND and non-visualization at preoperative imaging. The
Fig. 3 A 48-year-old woman
with a ductal carcinoma relapse in
the left breast, without SN
visualization on planar image (a).
Volume rendering of SPECT/CT
(b) shows a focus in level 1 of the
contralateral axilla (figure c)
corresponding with a non-
enlarged lymphatic node (circle)
on CT (d)
Fig. 4 A 61-year-old woman with ductal carcinoma relapse in the left
breast. (a) Late planar scintigraphy shows a lymphatic duct towards the
contralateral axilla. Also, a supraclavicular SN is visualized. (b) Volume
rendering shows both axillary and supraclavicular SNs together with a
focus medial to the injection site and altered anatomical configuration of
the left breast area due to primary treatment. (c) Supraclavicular SN on the
right. (d) Dorsal of the injection site two SN are visualized on SPECT/CT,
one intramammary and one intercostal, not visualized on planar
scintigraphy. Histopatology demonstrated micrometastasis in the
axil lary node whereas the intramammary, intercostal and
supraclavicular SN were negative
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intraoperative SN procedure was performed in 104 patients
but only in 71 of them the SN was identified and removed.
This resulted in a 68.3 % surgical SN resection rate. In seven
of these patients the SN could be identified using blue dye
only. Details concerning detection by gamma probe and/or
blue dye are given in Table 3.
At histopathology, SN metastases were found in 17/71 pa-
tients (23.9 %): eight with macrometastasis and nine with
micrometastasis. SN metastases were located outside the ipsi-
lateral axilla in 64.7 % of the cases (11/17) and in the contra-
lateral axilla in 29.4 % (5/17).
ALND was performed in 20 patients; with a total of
223 LN retrieved, median 11.2 nodes per patient (range 2
– 27). In 15 patients (75 %) histopathology showed no
further LN involvement, in 5 (25 %) macrometastases
were found. ALND did not reveal metastases in any of
the patients with a negative SN.
After surgical treatment of the relapse 60 patients received
hormone therapy, 43 chemotherapy and 30 radiotherapy, 38
patients received no further treatment.
Discussion
The results of the present study show that additional SPECT/
CT may play an essential role in patients with breast cancer
recurrence scheduled for the SN procedure.
From a clinical point-of-view probably the most im-
portant contribution of SPECT/CT is the information
provided to adjust the surgical approach. This concerned
over one in every five breast cancer relapse patients in
this study (21,3 %). The results achieved in our series
seem to be in a good agreement with data from the last
IAEA trial (17 % vs. 21 %); however, this small differ-
ence could be justified, firstly, due to the difference in
population, and secondly, due to the complicating fac-
tors associated to local recurrent cancer mentioned in
the introduction [18]. The adjustment of the surgical
approach may also lead to a better restaging in LCBR
patients as in the present study SN metastases were
located in ipsilateral territorial basins outside the axilla
or in the contralateral axilla in 16 out of 17 (94 %)
patients.
This surgical approach adjustment was particularly crucial
in three patients in whom SPECT/CT correctly identified pu-
tative SN visualization due to contamination artefacts and
avoided SN surgery. Similar artefact-related cases have been
Fig. 5 A 77-year-old woman
with ductal carcinoma relapse in
the left breast. Planar scintigraphy
shows bilateral foci parasternally
(a), arrows number 1 and 2.
SPECT/CT (b) shows the first
lower left focus as skin
contamination. Also, the focus
parasternally right appeared to be
due to skin contamination (c).
Note that a SN which was not
visualized on planar scintigraphy
is seen in level 1 of the right axilla
(contralateral) on SPECT/CT (d).
This axillary SN was negative for
metastasis
Table 3 Surgical sentinel node procedures and detection findings
N (patients)
Total scheduled SN procedures 122
Total performed SN 104
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reported in the multicentre IAEA SN trial, where 41 (out
1182) unnecessary SN surgeries could be avoided [18].
The superior anatomical information provided by SPECT/
CT was crucial to establish a 60 % territorial mismatch evi-
denced after the incorporation of SPECT/CT to the conven-
tional protocol based on PS. The anatomical information pro-
vided by SPECT/CT enabled nuclear physicians to accurately
localize SN in relation to specific lymph node basins and
anatomical landmarks.
For the present study static delayed images were acquired
3–4 h after intratumoral tracer injection. This delayed point of
time is based on the radiotracer biodistribution, which is com-
pleted at that moment (see the above mentioned reference).
Delayed imaging (planar and SPECT/CT) is important to ex-
clude eventual drainage outside of the ipsilateral axilla.
Theoretically, in patients with local relapse tracer migra-
tion from the injection site to SN is slower than in
patients without previous surgery and/or radiotherapy
of the breast/axilla. This was also observed in our se-
ries, in agreement with a previous study concerning SN
biopsy in patients with treated breasts [17].
Finally, SPECT/CT in this series led to detect more SNs
with almost 10 % improvement in the detection rate when
compared with conventional PS. These results are higher than
those reported in an earlier study in our hospital by van der
Ploeg et al. [23] and the more recently published multicenter
IAEA SN trial, both considering only untreated primary breast
cancer patients [18]. However, this detection improvement
related to SPECT/CT did not reach statistical significance
and probably a larger series of patients will be needed for a
definitive validation of the role of SPECT/CT.
Many factors affecting SN visualization have been largely
discussed in other papers. Some examples are: body mass
index (BMI), age at time of relapse, previous ALND, and
radiotherapy [16]. Also, recently, Vugts et al. analyzed multi-
ple variables and found that only previous radiotherapy had a
significant association with lower SN detection rates in LBCR
patients [24]; this could also explain the lower detection rates
in our series in comparison with the aforementioned series
[14, 15, 25–27].
An interesting concept and something probably worth of
further study is that there seems to be a tendency of lymphatic
regeneration after ALND and/or radiotherapy. A non-linear
association between time to relapse and SN detection rates
supports this idea. Cordoba et al. also suggested such a con-
cept [25]. The results in our series also show a nonlinear as-
sociation between the period of Brecovery^ (relapse-free
period) and an improvement in detection rate (Table 2).
Patients with breast cancer relapse within 10 years had a
46 % detection rate versus 62 % for patients with a relapse-
free period of more than 10 years. Blum et al. also proved that
neo-lymphatic vascularization was present in mice which had
undergone ALND-like surgery [28].
Conclusion
In conclusion, although not reaching statistical significance
the addition of SPECT/CT to the standard imaging protocol
for lymphatic mapping and SN localization in breast cancer
recurrence patients appears to improve detection of sentinel
nodes and their anatomical localization. This all may contrib-
ute to the adjustment of the surgical sentinel node approach
and a better staging mainly in patients presenting drainage
outside of the ipsilateral axilla.
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